Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke.
Publication/Presentation Date
11-7-2014
Abstract
Stroke is a leading cause of morbidity and mortality in the world. Low-dose methylene blue (MB), which has been used safely to treat methemoglobinemia and cyanide poisoning in humans, has energy enhancing and antioxidant properties. We tested the hypothesis that methylene blue treatment delays progression of at-risk tissue (ca. perfusion-diffusion mismatch) to infarct in permanent middle cerebral artery occlusion in rats at two MB treatment doses. Serial MRI was used to evaluate MB treatment efficacy. The major findings were: (i) MB significantly prolonged the perfusion-diffusion mismatch, (ii) MB mildly increased the CBF in the hypoperfused tissue, (iii) MB did not change the final infarct volume in permanent ischemic stroke, and (iv) there were no dose-dependent effects on mismatch progression for the 1 and 3mg/kg doses studied. This neuroprotective effect is likely the result of sustained ATP production and increased CBF to tissue at risk. This work has the potential to readily lead to clinical stroke trials given MB's excellent safety profile.
Volume
1588
First Page
144
Last Page
149
ISSN
1872-6240
Published In/Presented At
Rodriguez, P., Jiang, Z., Huang, S., Shen, Q., & Duong, T. Q. (2014). Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke. Brain research, 1588, 144–149. https://doi.org/10.1016/j.brainres.2014.09.007
Disciplines
Diagnosis | Medicine and Health Sciences | Other Analytical, Diagnostic and Therapeutic Techniques and Equipment | Radiology
PubMedID
25218555
Department(s)
Department of Radiology and Diagnostic Medical Imaging
Document Type
Article